CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...